Business Insider
31 Oct 2026, 10:10 UTC · 2h ago
Anthropic's IPO push includes a big bet on life sciences
Impact · against what's priced in
The news is largely immaterial for Eli Lilly as its high valuation is driven by GLP-1 dominance and production capacity, not productivity software adoption. Novartis receives a slight positive catalyst from the strategic alignment signaled by its CEO's board seat at Anthropic.
- LLY+0.00
Doesn't touch the price's assumptions
- The price assumes
Driver: 2026 Revenue Guidance ($85–87B)
While high Claude adoption among 50,000 employees is positive, it does not impact the primary valuation drivers of GLP-1 revenue guidance or manufacturing scale.
What LLY's price assumes · Sep 10
